What is HC Wainwright’s Forecast for REGENXBIO Q3 Earnings?

REGENXBIO Inc. (NASDAQ:RGNX) – Stock analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for REGENXBIO in a research note issued to investors on Friday, June 5th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will post earnings per share of $0.32 for the quarter, up from their previous forecast of $0.31. HC Wainwright currently has a “Buy” rating and a $26.00 target price on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($3.59) per share. HC Wainwright also issued estimates for REGENXBIO’s FY2027 earnings at ($4.04) EPS.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.36). REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%.The business had revenue of $6.39 million for the quarter, compared to analysts’ expectations of $25.84 million.

RGNX has been the topic of several other reports. Morgan Stanley set a $16.00 target price on shares of REGENXBIO in a research report on Friday, May 15th. Barclays dropped their price target on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, May 15th. Bank of America cut their price target on shares of REGENXBIO from $25.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. The Goldman Sachs Group lowered their price objective on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Tuesday, February 10th. Finally, Robert W. Baird set a $27.00 price objective on REGENXBIO in a report on Tuesday, February 10th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.55.

REGENXBIO Price Performance

NASDAQ RGNX opened at $6.08 on Monday. REGENXBIO has a 12 month low of $5.45 and a 12 month high of $16.19. The company has a 50-day moving average of $8.17 and a 200-day moving average of $10.41. The company has a market cap of $314.32 million, a P/E ratio of -1.09 and a beta of 1.04.

Insider Transactions at REGENXBIO

In related news, insider Steve Pakola sold 15,309 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $11.02, for a total transaction of $168,705.18. Following the completion of the sale, the insider owned 232,617 shares of the company’s stock, valued at approximately $2,563,439.34. This represents a 6.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 14.22% of the company’s stock.

Institutional Investors Weigh In On REGENXBIO

Several institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp increased its position in shares of REGENXBIO by 44.4% in the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares in the last quarter. Profund Advisors LLC lifted its holdings in shares of REGENXBIO by 11.8% during the 3rd quarter. Profund Advisors LLC now owns 14,444 shares of the biotechnology company’s stock valued at $139,000 after acquiring an additional 1,523 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of REGENXBIO by 0.8% during the 4th quarter. Deutsche Bank AG now owns 192,582 shares of the biotechnology company’s stock valued at $2,773,000 after acquiring an additional 1,527 shares in the last quarter. Captrust Financial Advisors boosted its position in REGENXBIO by 13.2% during the 4th quarter. Captrust Financial Advisors now owns 15,228 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 1,781 shares during the period. Finally, Diversified Trust Co boosted its position in REGENXBIO by 15.9% during the 1st quarter. Diversified Trust Co now owns 15,499 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 2,121 shares during the period. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.